SAB Biotherapeutics, Inc. (SABS)
Nasdaq: SABS · CIK 0001833214 · United States
Every official SAB Biotherapeutics, Inc. filing in one place: annual reports, quarterly results, current reports,
proxy statements, shareholding and announcements, straight from the regulator. Free to search.
Open SABS filings
SAB Biotherapeutics, Inc. documents
- SAB Biotherapeutics, Inc. 10-K 2026SABS 10-K 2026: annual report for fiscal 2026
- SAB Biotherapeutics, Inc. 10-K 2025SABS 10-K 2025: annual report for fiscal 2025
- SAB Biotherapeutics, Inc. 10-K 2024SABS 10-K 2024: annual report for fiscal 2024
- SAB Biotherapeutics, Inc. 10-K 2023SABS 10-K 2023: annual report for fiscal 2023
- SAB Biotherapeutics, Inc. 10-K 2022SABS 10-K 2022: annual report for fiscal 2022
- SAB Biotherapeutics, Inc. 10-Q 2026SABS 10-Q 2026: quarterly report for fiscal 2026
- SAB Biotherapeutics, Inc. 10-Q 2025SABS 10-Q 2025: quarterly report for fiscal 2025
- SAB Biotherapeutics, Inc. 10-Q 2024SABS 10-Q 2024: quarterly report for fiscal 2024
- SAB Biotherapeutics, Inc. 10-Q 2023SABS 10-Q 2023: quarterly report for fiscal 2023
- SAB Biotherapeutics, Inc. 10-Q 2022SABS 10-Q 2022: quarterly report for fiscal 2022
- SAB Biotherapeutics, Inc. 8-K 2026SABS 8-K 2026: current report for fiscal 2026
- SAB Biotherapeutics, Inc. 8-K 2025SABS 8-K 2025: current report for fiscal 2025
- SAB Biotherapeutics, Inc. 8-K 2024SABS 8-K 2024: current report for fiscal 2024
- SAB Biotherapeutics, Inc. 8-K 2023SABS 8-K 2023: current report for fiscal 2023
- SAB Biotherapeutics, Inc. 8-K 2022SABS 8-K 2022: current report for fiscal 2022
- SAB Biotherapeutics, Inc. DEF 14A 2026SABS DEF 14A 2026: proxy statement for fiscal 2026
- SAB Biotherapeutics, Inc. DEF 14A 2025SABS DEF 14A 2025: proxy statement for fiscal 2025
- SAB Biotherapeutics, Inc. DEF 14A 2024SABS DEF 14A 2024: proxy statement for fiscal 2024
- SAB Biotherapeutics, Inc. DEF 14A 2023SABS DEF 14A 2023: proxy statement for fiscal 2023
- SAB Biotherapeutics, Inc. DEF 14A 2022SABS DEF 14A 2022: proxy statement for fiscal 2022
- SAB Biotherapeutics, Inc. Form 4 2026SABS Form 4 2026: insider trading filing for fiscal 2026
- SAB Biotherapeutics, Inc. Form 4 2025SABS Form 4 2025: insider trading filing for fiscal 2025
- SAB Biotherapeutics, Inc. Form 4 2024SABS Form 4 2024: insider trading filing for fiscal 2024
- SAB Biotherapeutics, Inc. Form 4 2023SABS Form 4 2023: insider trading filing for fiscal 2023
- SAB Biotherapeutics, Inc. Form 4 2022SABS Form 4 2022: insider trading filing for fiscal 2022
- SAB Biotherapeutics, Inc. S-1 2026SABS S-1 2026: registration statement for fiscal 2026
- SAB Biotherapeutics, Inc. S-1 2025SABS S-1 2025: registration statement for fiscal 2025
- SAB Biotherapeutics, Inc. S-1 2024SABS S-1 2024: registration statement for fiscal 2024
- SAB Biotherapeutics, Inc. S-1 2023SABS S-1 2023: registration statement for fiscal 2023
- SAB Biotherapeutics, Inc. S-1 2022SABS S-1 2022: registration statement for fiscal 2022
- SAB Biotherapeutics, Inc. 13F 2026SABS 13F 2026: institutional holdings for fiscal 2026
- SAB Biotherapeutics, Inc. 13F 2025SABS 13F 2025: institutional holdings for fiscal 2025
- SAB Biotherapeutics, Inc. 13F 2024SABS 13F 2024: institutional holdings for fiscal 2024
- SAB Biotherapeutics, Inc. 13F 2023SABS 13F 2023: institutional holdings for fiscal 2023
- SAB Biotherapeutics, Inc. 13F 2022SABS 13F 2022: institutional holdings for fiscal 2022
More companies